JACOBS LEVY EQUITY MANAGEMENT, INC
Position in MGX — Metagenomi Therapeutics, Inc.
CIK 884414
FLORHAM PARK, NJ
Position in MGX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$512,085
+$431,105 QoQ
Shares Held
382,153
+1018.4% QoQ
Ownership
1.02%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $705,903,019 across 86 Biotechnology names. MGX ranks #66 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
214,160 | $165,468,582 | |
| 2 | INCY |
Incyte Corp
|
1,717,978 | $161,696,089 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
212,204 | $70,211,937 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
789,429 | $51,020,796 | |
| 5 | RARE |
Ultragenyx Pharmaceutical Inc.
|
1,431,071 | $29,980,937 | |
| 6 | EXEL |
Exelixis, Inc.
|
425,982 | $18,270,367 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,097,189 | $16,260,340 | |
| 8 | ARVN |
Arvinas, Inc.
|
1,441,521 | $15,280,122 |
All Filings in MGX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $512,085 | 382,153 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $80,980 | 34,169 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $50,570 | 34,169 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $90,007 | 66,182 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $238,917 | 66,182 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $296,474 | 136,624 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $180,156 | 44,156 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||